These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430 [TBL] [Abstract][Full Text] [Related]
5. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838 [TBL] [Abstract][Full Text] [Related]
6. Deferred therapy in patients with advanced disease. Smith PH Cancer; 1993 Feb; 71(3 Suppl):1074-7. PubMed ID: 8428330 [TBL] [Abstract][Full Text] [Related]
7. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma]. Stamey TA Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883 [TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG; Crawford ED; DeAntoni EP Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789 [TBL] [Abstract][Full Text] [Related]
10. [5/7 Prostate cancer in the elderly man]. Mourey L Soins Gerontol; 2010; (86):45-6. PubMed ID: 21298971 [No Abstract] [Full Text] [Related]
11. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. Arai Y; Yoshiki T; Yoshida O J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155 [TBL] [Abstract][Full Text] [Related]
12. The patient, disease status, and treatment options for prostate cancer: stages D1 and D2. Schmidt JD Prostate; 1983; 4(5):493-501. PubMed ID: 6351040 [TBL] [Abstract][Full Text] [Related]
13. What your patient needs to know about prostate cancer. Held-Warmkessel J Nursing; 2002 Dec; 32(12):36-42; quiz N232. PubMed ID: 12468938 [No Abstract] [Full Text] [Related]
14. Recent progress in the treatment of advanced prostatic cancer. Saini A; Waxman J Br J Hosp Med; 1992 Jan 23-Feb 4; 47(2):122, 125-6. PubMed ID: 1543959 [TBL] [Abstract][Full Text] [Related]
15. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer]. Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of prostate cancer]. Romics I Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076 [No Abstract] [Full Text] [Related]
17. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate]. Berenguer Sánchez A Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304 [No Abstract] [Full Text] [Related]
18. Prostate cancer in older men. Calabrese DA Urol Nurs; 2004 Aug; 24(4):258-64, 268; quiz 269. PubMed ID: 15446376 [TBL] [Abstract][Full Text] [Related]
19. Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. Labrie F; Cusan L; Gomez JL; Diamond P; Candas B J Clin Endocrinol Metab; 1995 Jul; 80(7):2002-13. PubMed ID: 7541800 [TBL] [Abstract][Full Text] [Related]